Helgi van de Velde Selected Research

Doxorubicin (Adriamycin)

1/2019	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
1/2018	Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
1/2018	Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.
10/2015	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
3/2015	Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Helgi van de Velde Research Topics

Disease

57	Multiple Myeloma 01/2022 - 02/2006
18	Neoplasms (Cancer) 12/2021 - 02/2006
10	Peripheral Nervous System Diseases (PNS Diseases) 01/2019 - 03/2011
8	Thrombocytopenia (Thrombopenia) 01/2022 - 06/2007
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019 - 12/2012
5	Neutropenia 01/2022 - 06/2007
5	Chromosome Aberrations (Chromosome Abnormalities) 12/2021 - 04/2008
4	Disease Progression 06/2019 - 08/2008
4	Fatigue 01/2018 - 02/2006
4	Infections 10/2015 - 08/2011
3	Castleman Disease (Castleman's Disease) 10/2015 - 07/2013
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2015 - 12/2011
2	Sepsis (Septicemia) 01/2022 - 08/2014
2	Pneumonia (Pneumonitis) 01/2022 - 08/2011
2	Diarrhea 10/2018 - 06/2007
2	Nausea 01/2018 - 08/2011
2	Lymphoma (Lymphomas) 01/2018 - 08/2011
2	Exanthema (Rash) 01/2017 - 04/2016
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2015 - 08/2014
2	Leukopenia 10/2015 - 07/2013
2	Hypertriglyceridemia 10/2015 - 07/2013
2	Hypercholesterolemia 10/2015 - 07/2013
2	Anemia 10/2015 - 07/2013
2	Multi-centric Castleman's Disease 05/2015 - 08/2014
2	Immunoglobulin Light-chain Amyloidosis 10/2014 - 07/2011
2	Fever (Fevers) 07/2013 - 08/2011
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 05/2013 - 08/2011
1	Infarction (Infarctions) 01/2022
1	Residual Neoplasm 01/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Plasmacytoma 01/2022
1	Thymoma (Thymic Carcinoma) 01/2022
1	Carcinogenesis 12/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Death (Near-Death Experience) 01/2017
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2015
1	Lymphopenia (Lymphocytopenia) 10/2015
1	Polycythemia (Erythrocytosis) 10/2015
1	Rheumatoid Arthritis 10/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2015
1	Amyloidosis 10/2014
1	Anaphylaxis (Anaphylactic Shock) 08/2014
1	Respiratory Tract Infections (Respiratory Tract Infection) 08/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2014
1	Heart Diseases (Heart Disease) 01/2014
1	Monoclonal Gammopathy of Undetermined Significance 01/2014
1	Smoldering Multiple Myeloma 01/2014
1	Anorexia 07/2013
1	Second Primary Neoplasms (Neoplasms, Second) 02/2013
1	Ovarian Neoplasms (Ovarian Cancer) 06/2012

Drug/Important Bio-Agent (IBA)

52	Bortezomib (Velcade)FDA Link 01/2019 - 02/2006
23	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 12/2011
19	Prednisone (Sone)FDA LinkGeneric 06/2019 - 10/2006
14	Melphalan (Alkeran)FDA LinkGeneric 06/2019 - 10/2006
11	Monoclonal AntibodiesIBA 01/2022 - 05/2013
11	isatuximabIBA 01/2022 - 01/2021
10	Proteasome InhibitorsIBA 01/2022 - 06/2012
10	siltuximabIBA 10/2015 - 05/2013
9	Lenalidomide (CC 5013)FDA Link 01/2022 - 04/2016
9	ixazomibIBA 07/2020 - 04/2016
8	pomalidomideIBA 01/2022 - 01/2021
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2019 - 01/2013
7	Rituximab (Mabthera)FDA Link 01/2019 - 08/2011
7	Interleukin-6 (Interleukin 6)IBA 10/2015 - 05/2013
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2015
5	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 03/2015
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2011
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017 - 02/2006
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 05/2013
3	InterleukinsIBA 10/2015 - 04/2014
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2021
2	AlbuminsIBA 01/2022 - 04/2008
2	Thalidomide (Thalomid)FDA Link 11/2015 - 01/2013
1	carfilzomibIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022
1	daratumumabIBA 01/2022
1	Inosine Monophosphate (IMP)IBA 06/2019
1	Capsules (Microcapsules)IBA 01/2018
1	Immunomodulating AgentsIBA 10/2017
1	CholesterolIBA 10/2015
1	HepcidinsIBA 10/2015
1	Amyloid (Amyloid Fibrils)IBA 10/2014
1	ErbB Receptors (EGF Receptor)IBA 04/2014
1	CytokinesIBA 03/2014
1	Hemoglobins (Hemoglobin)IBA 07/2013
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2013
1	DNA (Deoxyribonucleic Acid)IBA 11/2012
1	PlatinumIBA 06/2012

Therapy/Procedure

29	Therapeutics 01/2022 - 02/2006
8	Stem Cell Transplantation 07/2020 - 10/2006
4	Transplantation 06/2019 - 01/2013
3	Subcutaneous Injections 12/2012 - 12/2008
3	Intravenous Administration 12/2012 - 12/2008
2	Drug Therapy (Chemotherapy) 12/2021 - 08/2016
2	Intravenous Infusions 08/2011 - 05/2011
1	Retreatment 01/2019
1	VAP-cyclo protocol 03/2015
1	VMP regimen 06/2014
1	Drug Tapering 06/2014